What is Elicio Therapeutics Inc.?
, a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer.
The story behind the price, the case for and against, and what could go wrong. Open a part to read it.
, a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trials for seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 41.05M.
A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.